Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitotane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | CNR1 | P21554 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ATM | Q13315 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitotane SCHEMBL2352082 | 1.00 | TSHR (1.00) | TSHRHIF1AMAPK1TDP1CNR1 | |
| Mitotane SCHEMBL4040 | 1.00 | TSHR (1.00) | TSHRHIF1AMAPK1TDP1CNR1 | |
| Mitotane SCHEMBL4041 | 1.00 | TSHR (1.00) | TSHRHIF1AMAPK1TDP1CNR1 | |
| Mitotane SCHEMBL8937953 | 0.88 | CNR1 (0.78) | TSHRHIF1AMAPK1TDP1CNR1 | |
| Mitotane SCHEMBL8465001 | 0.87 | CNR1 (0.76) | TSHRHIF1AMAPK1TDP1CNR1 | |
| SCHEMBL29502468 | 0.85 | TSHR (0.73) | TSHRHIF1AMAPK1TDP1CNR1 | |
| SCHEMBL9130061 | 0.83 | TSHR (0.69) | TSHRHIF1AMAPK1TDP1CNR1 | |
| SCHEMBL7873189 | 0.79 | TSHR (0.66) | TSHRHIF1AMAPK1TDP1CNR1 | |
| Diethylstilbestrol SCHEMBL534253 | 0.79 | TSHR (0.62) | TSHRHIF1AMAPK1TDP1CNR1 | |
| SCHEMBL2937089 | 0.79 | TSHR (0.81) | TSHRHIF1AMAPK1TDP1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 979 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4594324-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2025-08-06 | — | — | EP | claimed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| US-20240317871-A1 | Anti-HVEM Antibodies | IMMUNOMIC THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | claimed |
| EP-4433462-A1 | USP9X INHIBITORS | Prodeg, LLC (US) | 2024-09-25 | — | — | EP | claimed |
| US-12083137-B2 | Triazole bisphosphonate geranylgeranyl diphosphate synthase inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-09-10 | — | — | US | claimed |
| US-20240239799-A1 | (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2024-07-18 | — | — | US | claimed |
| WO-2024068976-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-04 | — | — | WO | claimed |
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | claimed |
| EP-4345101-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-03 | — | — | EP | claimed |
| EP-4271712-A1 | ANTI-HVEM ANTIBODIES | Immunomic Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2023130012-A1 | COMPOUNDS FOR MUTANT KRAS PROTEIN DEGRADATION AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2023-07-06 | — | — | WO | claimed |
| WO-2023091464-A1 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | claimed |
| WO-2023089601-A2 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | claimed |
| EP-3544685-B1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEV CT BIOTECHNOLOGY (TW) | 2023-01-04 | — | — | EP | claimed |
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | claimed |
| WO-2022167682-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-11 | — | — | WO | claimed |
| EP-4039685-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-10 | — | — | EP | claimed |
| WO-2022147108-A1 | ANTI-HVEM ANTIBODIES | IMMUNOMIC THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | claimed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | TSHR 2166/4885HIF1A 2357/4885MAPK1 489/4885 |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN3 | TSHR 445/4885HIF1A 1707/4885MAPK1 242/4885 |
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | TSHR 1987/4885HIF1A 1633/4885MAPK1 196/4885 |
| US-12083137-B2 | Triazole bisphosphonate geranylgeranyl diphosphate synthase inhibitors | GGPS1, FDPS, HPGDS | TSHR 3976/4885HIF1A 3918/4885MAPK1 1568/4885 |
| US-20240239799-A1 | (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER | PTPN1, PTPN5, PTPRJ | TSHR 1010/4885HIF1A 2807/4885MAPK1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.